DermatologyNews.net

Dermatology Xagena

Search results for "Enbrel"

FDA ( Food and Drug Administration ) approved an expanded indication for Enbrel ( Etanercept ) to improve physical function in patients with psoriatic arthritis. In addition, the FDA approved an up ...


The results from the head-to-head phase III FIXTURE study showing Secukinumab ( AIN457 ), an interleukin-17A ( IL-17A ) inhibitor, was significantly superior to Etanercept ( Enbrel ) in moderate-to-se ...


OBSERVE-5 was a 5-year FDA-mandated surveillance registry of patients with psoriasis. Researchers have assessed long-term Etanercept ( Enbrel ) safety and effectiveness. Patients with moderate to s ...


Results from two pivotal phase III studies evaluating the interleukin-17A ( IL-17A ) inhibitor Secukinumab ( AIN457 ) were published in the New England Journal of Medicine ( NEJM ). Secukinumab met ...


The phase IIIb CLEAR study for Secukinumab ( Cosentyx ) has demonstrated superiority to Ustekinumab ( Stelara ) and met its primary endpoint of achieving PASI 90, which represents clear or almost clea ...


In clinical practice, patients with psoriasis may require intermittent therapy as part of their long-term treatment programme. Those achieving Physician's Global Assessment ( PGA ) of less than or equ ...